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Introduction
 Febrile neutropenia is a relatively frequent event in 
cancer patients treated with chemotherapy. In the United 
States, an estimated 60,000 patients a year are hospitalized 
for febrile neutropenia and neutropenia related infections 
(Cagganio et al., 2005). Our single institution data in 
previous two studies have shown the frequency to be 
ranging from 10 to 12 per month (Lal et al., 2008; Shaikh 
et al., 2011).
	 Defined	 as	 “A	 single	 oral	 temperature	≥38.0°C	 for	
≥1	 hour	with	 a	 neutrophil	 count	 of	 ≤	 0.5x109/L or a 
neutrophil	 count	 of	 ≤	 1x109/L which was predicted to 
fall	below	≤	0.5x109/L (Pettengell et al., 2011), febrile 
neutropenia is a potentially life threatening situation and 
requires prompt medical intervention The availability of 
antibiotics have dramatically improved the outcome at the 
expense	of	increased	cost	(Kuderer	et	al.,	2007)	and	hence	
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Abstract
 Introduction: Febrile neutropenia is a relatively frequent event in cancer patients treated with chemotherapy 
and improvement in absolute neutrophil count (ANC) has been linked directly to improved outcome. Evaluation 
of granulocyte colony stimulating factors (GCSFs) for treatment has shown reduced incidences of episodes of 
prolonged neutropenia and protracted hospitalization. To determine absolute neutrophil counts with GCSF in 
febrile neutropenic cancer patients admitted to a tertiary care centre and to co-relate the improvement in ANC 
with mortality and hospital discharge. Methods: A prospective cross sectional study was carried at an oncology 
ward at Aga Khan University hospital from January 2010 to June 2011. All adult patients who were admitted 
and treated with GCSF for chemotherapy induced febrile neutropenia were included. Multivariable regression 
was conducted to identify the factors related with poor outcomes. Results: A total of 131 patients with febrile 
neutropenia were identified with mean age of 43.2 (18-85) years, 79 (60%) being ≤50. Seventy-five (57%) had 
solid tumors and 56 (43%) hematological malignancies, including lymphoma. Fifty seven (43.5%) had an ANC 
less 100 cells/mm3, 34 (26%) one between100-300 cells/mm3 and 40 (31%) an ANC greater than 300 cells/mm3. 
Thirty (23%) patients showed ANC recovery in 1-3 days, and 74(56%) within 4-7 days. Thirteen (10%) patients 
showed no recovery. The overall mortality was 18 (13.7%) patients. The mean time for ANC recovery seen in 
hematological malignancies was 6.34 days whereas for solid tumors it was 4.88 days. Patients with ANC <100 
cells/mm3 were more likely to die than patients with ANC >300 cells/mm3 by a factor of 4.3. Similarly patients 
>50 years of age were 2.7 times more likely to die than younger patients. Conclusion: Our study demonstrated 
that use of GCSF, in addition to intravenous antibiotics, in treatment of patients with chemotherapy induced 
febrile neutropenia accelerates neutrophil recovery, and shortens antibiotic therapy and hospitalization. We 
propose to risk classify the patients at the time of admission to evaluate the cost effectiveness of this approach 
in a resource constrained setup. 
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a substantial economic burden on patients and families 
(Carbonero et al., 2001).
	 Hemopoietic	 colony	 stimulating	 factors,	 such	 as	
G	CSF	 and	GM	CSF	 have	 been	 shown	 to	 promote	
proliferation, differentiation and functions of progenitor 
and mature cells of myeloid lineage (Souza et al., 1986). 
These cytokines circulate bactericidal functions of mature 
neutrophil	 (Metcalf	 et	 al.,	 1990).	When	 administered	
as a preventive adjunct to chemotherapy, CSF’s have 
shown in clinical trials to shorten neutropenic period and 
reduce	50%	 incidences	 of	Febrile	Neutropenia	 in	 high	
risk	patients	(Crawford	et	al.,	1991).	Also	the	effect	of	G	
CSF	and	GM	CSF	in	increasing	the	number	of	neutrophil	
has provided the background for clinical studies designed 
to assess their role as an adjunct therapy to antibiotics in 
febrile neutropenia (Clarke et al., 2005). The improvement 
in absolute neutrophil count has been linked directly to the 
improved outcome of patients with febrile neutropenia. 
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Some studies have evaluated the role of CSF’s in the 
treatment	 Febrile	 neutropenia	 (Maher	 et	 al.,	 1994;	
Riikonen	et	al.,	1994;	Mayordomo	et	al.,1995)	and	showed	
reduced	incidences	of	episodes	of	prolonged	Neutropenia	
and protracted hospitalization among cytokine treated 
patients but cost effectiveness of this approach for resource 
restricted settings is debatable. Therefore, we conducted 
this study to evaluate the role of G CSF in the treatment 
of	patients	with	Febrile	Neutropenia	and	to	justify	its	use	
in resource constrained setting on the basis of evidence.
 To determine the improvement of absolute neutrophil 
count	with	GCSF	in	Febrile	Neutropenic	cancer	patients	
admitted to a tertiary care centre. To co-relate the 
improvement	 in	ANC	with	 the	mortality	 and	 hospital	
discharge among patients who were administered 
Granulocyte colony stimulating factor and determine their 
outcomes based on recovery or mortality
 
Materials and Methods
 This is a prospective cross sectional study conducted 
from	 January	 2010	 to	 June	 2011.	All	 patients18	 years	
and above admitted with the diagnosis of chemotherapy 
induced neutropenic fever (Pettengell et al., 2011) under 
hematology	 and	 oncology	 services	 at	The	Aga	Khan	
University	Hospital	(AKUH)	were	included.	The	AKUH	
is	a	renowned	560	bedded	tertiary	care	center	in	Karachi,	
Pakistan	The	data	set	included	the	information	on	age,	sex	
and	types	of	cancers,	WBC	counts	with	differential	counts	
at presentation, number of Chemotherapy cycles and 
days	since	last	cycle.	All	patients	were	initially	evaluated	
in	 the	 emergency	 room	 or	 clinic.	A	 comprehensive	
history,	physical	examination,	necessary	laboratory	and	
radiological investigations were done on all the patients. 
All	 febrile	 neutropenic	 patients	were	 treated	 initially	
empirically with broad spectrum intravenous antibiotics 
and Granulocyte colony stimulating factors (G CSF) 
at dose of 5 micrograms/kg subcutaneously. Emperic 
antibiotics	were	modified	 later	based	on	culture	results	
However,	for	decision	of	vancomycin	and	amphotericin	B	
was based on established guidelines for the management 
of	febrile	neutropenia	(Carbonero	et	al.,	2001).	All	patients	
were managed in the oncology unit while neutropenic 
septic shock patients were managed in intensive care 
unit. Treatment with GCSF was discontinued as soon as 
ANC	rose	above	1500	cells/mm3.	Blood	products	were	
transfused as per requirement of individual patient.
Study Variable
 Study outcome, death / discharged. 
Independent variables
	 Age	was	collected	as	continuous	later	categorized	as	
<50	and	>50	years.	Similarly	ANC	at	presentation	was	also	
collected as continuous, later arbitrary cutoff was created 
based on the presentation of data as less than 100cells/
mm3, between 100-300 cells/mm3 and more than 300cells/
mm3
Statistical analysis 
 Data are summarized as relative frequencies for 
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categorical variables and mean (SD) for normally 
distributed continuous variables. Comparisons between 
groups were performed using Student t test and Pearson 
Chi-square according to the variables type and distribution. 
To	 explore	 the	 relationship	 between	use	 of	GCSF	 and	
outcome (death and discharged), logistic regression model 
was employed with adjustment for potential confounders. 
Significance	level	was	established	as	a	two	tailed	p-Value	
≤0.05.	Calculations	were	made	with	SPSS	17.0,	Chicago,	
U.S.A.
Results 
Patients
	 Total	of	131	patients	with	febrile	neutropenia	identified	
during	 the	 study	 period.	The	mean	 age	was	 43.2	 (18-
85)	years.	There	were	 slightly	more	patients	79	 (60%)	
who were <50 years of age. There was almost equal 
gender distribution with 66 males and 65 females. Only 
36 patients had other co-morbids related to health like 
diabetes mellitus, chronic obstructive pulmonary disease, 
or congestive cardiac failure. 
	 There	were	75	(57%)	patients	with	solid	tumors	and	
56	 (43%)	with	 hematological	malignancies	 including	
lymphoma.	More	patients	86	(66%)	were	receiving	the	
curative treatment in adjuvant setting while remaining 
received the palliative treatment. The demographics of 
the study patients is shown in the Table 1.
ANC recovery
 The patients who had recovered and were discharged 
had	mean	ANC	of	282	cells/mm3 at presentation, whereas 
patients	who	died	had	mean	ANC	of	127	cells/mm3 (P 
value	0.001).	There	were	57	(43.5%)	patients	with	ANC	
less 100 cells/mm3,	34	(26%)	between	100-300	cells/mm3 
Table 1. Baseline Demographic and Clinical 
Characteristics of Patients Receiving GCSF
Characteristics																																																	No.	of	Patients
Median	age,	years	(Range)	 43.3	years	 (18-85)
Sex,	Male/Female	 66/65
Types of cancer (%) merge as discussed:
HEMATOLGICAL	MALIGNANCIES
	 a.	Lymphoma	 36	 (27.5%)
 b. Leukemia 20 (15.3%)
SOLID	TUMOUR
      a. Sarcoma 21 (16%)
						b.	Head	&	Neck	 09	 (6.9%)
	 c.	Lung	 07	 (5.3%)
	 d.	Breast	 15	 (11.5%)
 e. Genitourinary 15 (11.5%)
 f. Gastrointestinal 08 (6.1%)
Chemotherapy given with 
	 Curative/Palliative	intent	 86/45
Median	WBC	at	presentation	 700/mm3 (100-3100)
	 Median	ANC	at	presentation	 119/mm3 (0-1000)
	 ANC	<100/mm3,	No.(%)	 58	 (44.2%)
	 ANC	b/w	100-500/mm3,	No.(%)	 55	 (41.9%)
	 ANC	b/w	500-1000/mm3,	No.(%)	 18	 (13.7%)
Median	Monocyte		at	Presentation	 70	(0-1100)
Median	No.	of	Days	since	last	cycle,	No.(Range)	10	 (1-51)
Median	No.	of	previous	cycle,	No.(Range)	 2	 (1-15)
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Table 2. Crude Unadjusted Odds Ratios for Predictor 
of Poor Outcome in Patients Admitted with Febrile 
Neutropenia.
Variable													Discharged		 				Death		 	P-value		Un-		95%	CI
                                                                           adjusted 
             Odds Ratios
Age	(years)	 	 	 	 	
	 >50	 48	(	42.5)	 4	(	22.2)	 1	
	 ≤	50	 65	(	57.5)	 14	(	77.8)	 0.1	 0.38	 0.12-1.2
Gender      
	 Male	 55	(	48.7)	 11	(	61.1)	 	 1	
	 Female	 58	(	51.3)	 7	(38.9)	 0.32	 0.6	 0.2-1.6
Types Of Cancer     
	 Solid	 66	(	58.4)	 9	 (	50)	 	 1	
	 Hematological	 47	(41.6)	 9	 (50)	 0.5	 0.7	 0.2-1.9
ANC	At	Presentation	
	 	 283	(	29.4)	 127	(30.4)	 0.001	1.1	 1.0-1.1
ANC	At	Presentation	 	 	 	 	
 >300 38 ( 33.6) 2 (11)  1 
	 <100	 47	(41.6)	 10	(55.6)	 0.07	 4.1	 1.1-19.5
	 100	-	300	 28	(24.8)	 6	(33.3)	 	 4	 1.3-21.6
Co	Morbidities		 	 	 	 	
	 No	 82	(	72.6)	 13	(	72.2)	 	 1	
	 Yes	 31	(	27.4)	 5	(	27.8)	 0.97	 0.98	 0.3-2.9
Intent Of Treatment      
	 Curative	 77	 (	68)	 9	 (	50)	 	 1	
	 Palliative	 36	(	31.9)	 9	 (	50)	 0.13	 0.46	 0.1-1.2
Monocyte	At	Presentation		
  190 ( 26.1) 39 (12.1) 0 1.1 1.1-1.2
Days	To	ANC	Recovery		 	 	 	 	
	 No	Recovery	 1	 (0.9)	 12	(66.7)	 	 --	
 1-3 Days 30 (26.5) 0  0 --
	 4-7	 70	(61.9)	 4	(22.2)	 	 --
	 Beyond	7	Days	12	(10.6)	 2	 (11.1)	 	 --
Table 3. Multivariable Analysis Along with Adjusted 
Odds Ratios and 95% CI for Predictor of Poor Outcome 
in Patients Admitted with Febrile Neutropenia
Variables										Odds	Ratios	(Adjusted)					95%	CI							P-value
Monocyte	At	Presentation		
 >300 1  
	 <100	 4.3	 1.2-21	 0.05
	 100	-	300	 4	 1.1-22	
Age	(years)	 	 	
 >50 1  
	 ≤	50	 2.7	 2.8-9.1	 0.04
and	40	(30.5%)	greater	than	300	cells/mm3.  Thirty (23%) 
patients	 showed	ANC	 recovery	 in	 1-3	 days,	while	 74	
(56%)	patients	had	ANC	recovery	in	4-7	days.	Fourteen	
(10.6%)	had	ANC	recovery	in	more	than	7	days.	Thirteen	
(10%)	patients	showed	no	recovery	in	ANC	counts.	The	
overall	mortality	 resulted	 in	 18	 (13.7%)	 patients.	The	
mean	 time	 for	ANC	 recovery	 seen	 in	 hematological	
malignancies	was	6.34	day.	Whereas,	mean	time	for	ANC	
recovery	seen	in	solid	tumors	was	4.88	days.
	 Mean	monocyte	at	presentation	was	190	cells/mm3 in 
patients who were discharged and 39 cell/mm3 in patients 
who died during hospital stay (P value = 0.00) Table 2. 
	 One	hundred	&	thirteen	(86%)	patients	had	recovered	
from febrile neutropenia and were discharged from 
hospital	 out	 of	which	101	 (78%)	patients	 had	hospital	
course	of	less	than	7	days.
	 There	were	57	patients	with	ANC	less	100	cells/mm3 of 
which	47	patients	were	discharged	and	39	had	hospital	stay	
less	than	7	days.	Thirty	four	patients	had	ANC	between	
100-300 cells/mm3 of which 28 were discharged. Forty 
patients	had	ANC	greater	than	300	cells/mm3 of which 38 
were discharged.
Multivariable regression 
 Our multivariable analysis Table 3 shows that, odds of 
ANC	at	presentation	<100	cells/mm3 are	4.3	times	more	
likely	to	die	compare	to	those	with	ANC	>300	cells/mm3. 
Similarly	 patients	with	ANC	100-300	 cells/mm3	 are	 4	
times more likely to die, adjusting for all other variables. 
Similarly, after adjusting for other covariates the effects 
of age suggests that those with greater than 50 years are 
2.7	times	more	likely	to	die	as	compare	to	those	with	age	
less than 50 years (Table 3).
 
Discussion
Our study demonstrated that the age was a predictor 
of poor outcome in patients admitted with febrile 
neutropenia. Patients younger than 50 years of age gained 
more	benefit	 in	primary	 endpoints	 from	 routine	use	of	
GCSF	as	compared	to	older	patients	by	factor	of	2.7.
Patients older than 50 years of age had more co 
morbidities which also were associated with higher 
mortality or worse outcomes as previously studied ( 
Kuderer	et	al.,	2006).Also,	the	ANC	of	less	than	100	was	
associated with the worst outcome. Our study population 
was heterogeneous as far as diagnoses and treatments 
were	considered.	Most	of	our	patients	were	younger	than	
50 years (60%) and this population of patients had a better 
outcome. The gender distribution was equal in the study 
group, but mortality had a slight male predominance. The 
overall	mortality	was	13.7%	which	is	comparable	from	
international	studies	(Berghmans	et	al.,	2002)
Use of GCSF did improve the outcome in older 
patients and assumed to decrease the mean duration of 
hospital	stay.	However,	it	remained	debatable	whether	this	
was	a	cost	effective	strategy	or	not	especially	when	34%	
of our study patients received chemotherapy for metastatic 
disease.	Monocytemia	 at	 presentation	 has	 been	 shown	
to be associated with worse outcomes in the literature 
(Rankoff	 et	 al.,	 1996).	Monocytemia	 is	 linked	with	
bacteremia in children with febrile neutropenia (Rankoff 
et al., 1996) and monocytemia after chemotherapy is 
correlated neutropenia while monocytosis indicates 
neutrophil recovery (Oguz et al., 2006). This was seen in 
our study as well, as in present study there was a trend 
towards	significantly	better	outcomes	in	patients	with	high	
monocyte	 count	 at	 presentation.	Hence,	 for	 a	 resource	
constrained setup, this simple parameter can be followed 
at presentation in addition to other variables to predict 
the course of the patient and GCSF can be avoided in 
patients	with	good	monocyte	count.	Majority	of	patients	
had	ANC	recovery	in	3	to	7	days.	Mean	ANC	recovery	
in Solid tumours was slightly better than hematological 
malignancies probably because bone marrow takes longer 
time to recover in treatment of acute leukemias and even 
in lymphomas. Similar recovery patterns were observed 
in	(Maher	et	al.,	1997;	Carbonero	et	al.,	2001)	studies.	
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However	when	compared	with	(Ghaulat	et	al.,	2008),	the	
ANC	recovery	in	hematological	malignancies	seen	in	our	
patients	were	significantly	better.
Delayed	ANC	 recovery	was	 associated	with	 longer	
periods of hospitalization which not only increases the 
cost but also adversely affect the outcome. In our study 
14	(10.6%)	patients	took	longer	than	7	days	for	ANC	to	
recover and hence had longer hospital stay. These results 
suggested	that	age,	ANC	and	monocytes	at	presentation	
and types of malignancy were independent indicators of 
patients	outcome.	We	observed	that	younger	patients	who	
received GCSF recovered and were discharged home, 
similarly	 older	 patients	with	 better	ANC	 and	 higher	
monocytes	 at	 presentations	 also	 recovered	 quickly.	A	
study previously done at our institution showed that 
hematological malignancies, age above 50 years, severity 
of dehydration, pneumonia and positive blood cultures 
were	significantly	associated	with	increase	in	length	of	
hospital stay and mortality, but the study did not mention 
whether the study subjects received G CSF or not (Lal et 
al., 2008).  In another study, independent indicators like 
ECOG	≥	2,	chronic	obstructive	airway	disease,	chronic	
heart	failure,	stomatitis	grade	≥	2,	monocytes	<200mm3 
and hyperglycemia have been studied for prognostic 
evaluation in apparently stable patients with febrile 
neutropenia. These simple assessments can classify cancer 
patients with febrile neutropenia according to risk of 
complication	(Carmonera-Bayonas	et	al.,	2011).
GCSF treatment offers substantial potential for saving 
lives of hospitalized patients with established neutropenia 
over a wide range of model assumption and our study 
showed	the	similar	results	(Cosler	et	al.,	2007).	Our	study	
results though very pertinent but cannot be generalized as 
this was a single centre cross sectional study. It revealed 
that	delayed	ANC	recovery	prolonged	the	hospitalization	
and	 adversely	 affects	 the	 outcome.	We	 have	 seen	 the	
benefit	of	GCSF	in	our	patients	despite	the	minimal	benefit	
of GCSF in established febrile neutropenic patients in 
the	reported	literature.	(Maher	et	al.,	1997;	Carbonero	et	
al., 2001). Therefore, we suggest using GCSF in febrile 
neutropenia for every patient admitted to hospital. The 
(Cabonero et al., 2001) model can be incorporated in the 
initial assessment of patients along with the monocyte 
count at presentation for considering the decision for 
GCSF for high risk patients where cost is the major 
limiting factor. 
In conclusion, our study demonstrates that use of G 
CSF, in addition to intravenous antibiotics, in treatment of 
patients	with	chemotherapy	induced	Febrile	Neutropenia	
accelerates neutrophil recovery, shortens antibiotic therapy 
and	hospitalization.	We	propose	to	risk	classify	the	patients	
at the time of admission to evaluate the cost effectiveness 
of this approach in resource constrained setup.
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